GALIG Gene Expression in Parkinson's Disease

NCT ID: NCT02923297

Last Updated: 2020-09-01

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 37 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-04-30
• Study Completion Date: 2015-06-30

Brief Summary

Parkinson's disease (PD) is the most frequent neurodegenerative disorder after Alzheimer's disease. It is characterized by motor symptoms (rigidity, tremor, slowness of movements), and non-motor symptoms (neuropsychological, psychiatric, pain ...). Neuronal death initiates in the brainstem and extends progressively through the entire cortex. The processes leading to cell death are poorly understood. Pathological cells exhibit abnormal deposits, called Lewy bodies, which contain numerous proteins. A major constituent of these protein deposits is alpha-synuclein. It has recently been demonstrated, in the Laboratory of Molecular Biophysics of the CNRS (Scientific Research National Center) in Orleans, that α-synuclein interacts with Cytogaligin, a protein produced by the proapoptotic GALIG gene. Cytogaligin could thus be a factor regulating α-synuclein activity or aggregation. It is postulated that the level of expression of the GALIG gene is different in Parkinson's disease patients compared with control subjects.

Conditions

Parkinson Disease

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: NONE

Study Groups

Parkinson's disease patients

blood sampling

Group Type: OTHER

Blood sampling

Intervention Type: OTHER

blood sampling for determine and compare the expression patterns of GALIG gene

Interventions

Blood sampling

blood sampling for determine and compare the expression patterns of GALIG gene

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Patients with Parkinson's Disease according to the criteria of the UKPDBB (UK Parkinson's disease brain bank).

Exclusion Criteria

• Insane patient arriving without a third party.
• Patient with Parkinson's disease arising from another etiology.

• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Scientific Research Centre

UNKNOWN

Sponsor Role: collaborator

Centre Hospitalier Régional d'Orléans

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Canan OZSANCAK, Ph

Role: PRINCIPAL_INVESTIGATOR

CHR d'ORLEANS

Locations

CHR d'ORLEANS

Orléans, , France

Countries

France

References

Alieva AKh, Filatova EV, Karabanov AV, Illarioshkin SN, Slominsky PA, Shadrina MI. Potential Biomarkers of the Earliest Clinical Stages of Parkinson's Disease. Parkinsons Dis. 2015;2015:294396. doi: 10.1155/2015/294396. Epub 2015 Sep 21.

Reference Type: BACKGROUND

PMID: 26483988 (View on PubMed)

Pinho R, Guedes LC, Soreq L, Lobo PP, Mestre T, Coelho M, Rosa MM, Goncalves N, Wales P, Mendes T, Gerhardt E, Fahlbusch C, Bonifati V, Bonin M, Miltenberger-Miltenyi G, Borovecki F, Soreq H, Ferreira JJ, F Outeiro T. Gene Expression Differences in Peripheral Blood of Parkinson's Disease Patients with Distinct Progression Profiles. PLoS One. 2016 Jun 20;11(6):e0157852. doi: 10.1371/journal.pone.0157852. eCollection 2016.

Reference Type: BACKGROUND

PMID: 27322389 (View on PubMed)

Scherzer CR, Eklund AC, Morse LJ, Liao Z, Locascio JJ, Fefer D, Schwarzschild MA, Schlossmacher MG, Hauser MA, Vance JM, Sudarsky LR, Standaert DG, Growdon JH, Jensen RV, Gullans SR. Molecular markers of early Parkinson's disease based on gene expression in blood. Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):955-60. doi: 10.1073/pnas.0610204104. Epub 2007 Jan 10.

Reference Type: BACKGROUND

PMID: 17215369 (View on PubMed)

Other Identifiers

CHRO-2014-05

Identifier Type: -

Identifier Source: org_study_id